Novo Nordisk
Mentioned in 71 analyzed podcast episodes across 10 shows
A Danish pharmaceutical company and global market leader in GLP-1 weight loss and diabetes drugs, primarily known for Ozempic and Wegovy. Novo Nordisk has faced significant stock declines and market challenges due to disappointing trial results, pricing pressure from competitors like Eli Lilly, legal battles with telehealth compounders, and subsequent announcements of major price cuts (up to 50%) starting 2027. The company also controls approximately 74% of global insulin supply and has been discussed across financial and healthcare podcasts regarding patent cliff exposure, reimbursement delays, and litigation over side effect warnings.
Mentioned On
Episode Mentions
The Dr. Gabrielle Lyon Show · May 19, 2026
The Cancer Doctors Keep Missing in Young Adults - Dr. Michelle Pearlman
“Manufacturer of GLP-1 medications including Ozempic, Wegovy, and Saxenda; discussed extensively regarding delivery systems and dosing”
Mind Pump: Raw Fitness Truth · May 16, 2026
2859: Take a Week Off and Gain 21% More Muscle — Here's the Science
“Produces semaglutide (Ozempic/Wegovy), competing in the rapidly expanding GLP-1 pharmaceutical market”
Rich Habits Podcast · May 14, 2026
Q&A: $1.3M IRA, Aging Parents & SpaceX's IPO
“Pharmaceutical company identified by AI-generated asset strategy for peptide market exposure”
Pharma and BioTech Daily · May 13, 2026
Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily
“Divested Parkinson's Cell Therapy Project (STEM PD) to Cellular Intelligence for regenerative medicine focus”
Rich Habits Podcast · May 8, 2026
Anthropic & SpaceX Partnership, GameStop Buying eBay & Data Centers In Your House
“Launching oral Ozempic pill available through Amazon Pharmacy for same-day delivery at $25-149/month”
The Ezra Klein Show · May 8, 2026
GLP-1s and the ‘Wild West’ of Wellness
“Manufacturer of semaglutide (Ozempic, Wegovy), the first major GLP-1 drug driving current adoption wave”
Pharma and BioTech Daily · May 7, 2026
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
“Advancing GLP amylin combo Cagrosima and obesity treatment Wegovi with $355M quarterly revenues despite technical setbacks”
Wall Street Breakfast · May 6, 2026
Soda & chips: McDonald's and AMD in focus
“Oral Wegovy success expected to offset sales declines in other product categories”
WSJ What’s News · May 6, 2026
Samsung Hits $1 Trillion Milestone as AI Demand Soars
“Weight-loss drug maker beat Q1 expectations with 30% sales surge, launching obesity pill with 2 million users despite Eli Lilly competition”
WSJ Minute Briefing · May 6, 2026
Samsung Joins The Trillion Dollar Club
“Maker of Wegovy obesity drug reported 30% Q1 sales surge and launched obesity pill with 2M prescriptions”
Stock Movers · May 6, 2026
Novo Nordisk's Pill, BMW's Struggle, Diageo Up
“Obesity drug maker's WeGoV pill showing strong sales momentum, gaining market share against Eli Lilly with shares up 9%”
Stock Movers · May 6, 2026
Novo Nordisk's Pill, BMW's Struggle, Diageo Up
“Weight loss pill achieved 2M+ US prescriptions in Q1, driving strong sales and stock gains despite Eli Lilly competition”
On The Pen GLP-1 News · May 5, 2026
He Took Retatrutide 40mg and Proved a Point
“Earnings call scheduled; competitor in GLP-1 market with Wegovy/Ozempic; referenced as market comparison point”
ZOE Science & Nutrition · Apr 30, 2026
Should you take Ozempic? The 5 things you need to know before starting GLP-1 drugs | Dr Ania Jastreboff
“Manufacturer of Ozempic (semaglutide) and Saxenda, key GLP-1 drugs discussed throughout episode”
Skin Anarchy · Apr 28, 2026
What “Efficacy” Actually Means in Skincare with Jack Jia of Musely
“Manufacturer of Ozempic, discussed as example of accidental wellness crossover and suboptimal business model for non-life-threatening conditions”
CNBC's "Fast Money" · Apr 24, 2026
Intel Posts Best Day Since 1987 and Counting Down to Big Tech Results 4/24/26
“Benefiting from Lilly's softer demand; valuation gap vs Lilly narrowing; 12x vs 26x multiples”
Pharma and BioTech Daily · Apr 24, 2026
Regeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech Daily
“Announced positive clinical trial results for oral semiglutide extending beyond obesity to adolescent type 2 diabetes treatment”
Pharma and BioTech Daily · Apr 23, 2026
Amneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech Daily
“Competing with Eli Lilly for dominance in oral GLP-1 weight loss drug market”
How I Invest with David Weisburd · Apr 22, 2026
E353: Why Biotech Is Struggling in Today’s Market (and the Future of Healthcare)
“Competitor to Lilly in GLP-1 space; losing market share and facing low earnings multiples due to weak pipeline behind GLP-1.”
WSJ What’s News · Apr 22, 2026
Can a Chatbot Be Charged With Murder?
“Wegovy weight loss drug now available through Amazon's new pharmaceutical delivery program”
The AI Podcast · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major enterprise partnership with OpenAI for AI deployment across drug discovery, clinical trials, manufacturing, and supply chain”
Claude AI · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major partnership with OpenAI for AI deployment across drug discovery, clinical trials, manufacturing, and supply chain by end of 2026”
Anthropic · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major partnership with OpenAI to deploy AI across drug discovery, clinical trials, manufacturing, and supply chain with full deployment by end of 2026”
AI Breakdown · Apr 21, 2026
New Apple CEO, OpenAI's New Image Model, Vercel AI Hack
“Signed major partnership with OpenAI for AI deployment across drug discovery, clinical trials, manufacturing, and supply chain by end of 2026”
The Dr. Gabrielle Lyon Show · Apr 21, 2026
GLP-1 Side Effects, Risks, And Who Should Actually Be Using It | Dr. Christle Guevarra
“Manufacturer of semaglutide (Ozempic) and tirzepatide (Mounjaro/Zepbound), primary GLP-1 medications discussed”
CNBC's "Fast Money" · Apr 14, 2026
Big Tech Bounce… And An Economic Warning From JPMorgan CEO Jamie Dimon 4/14/26
“Partnering with OpenAI on AI for drug discovery; stock down 23% year-to-date despite partnership”
Armstrong & Getty On Demand · Apr 2, 2026
Oh My God I Hate The Left
“Manufacturer of Wegovy pill, competitor to Mounjaro with more restrictive dosing requirements”
PBS News Hour - Full Show · Apr 1, 2026
April 1, 2026 - PBS News Hour full episode
“Competitor in weight loss pharmaceutical market with Uygovy pill, which Foundayo follows as second daily oral medication”
Mad Money w/ Jim Cramer · Apr 1, 2026
Mad Money w/ Jim Cramer 4/1/26
“Competitor in GLP-1 weight loss pill market with slightly better efficacy but inferior convenience compared to Lilly's Foundail”
CNBC's "Fast Money" · Apr 1, 2026
Markets Rally Ahead of Trump’s Iran Address… And Fading The Bounce 4/1/26
“Oral Wegovy pill shows 17% weight loss efficacy, launched earlier in 2026, competing with Eli Lilly's Fondayo in GLP-1 market”
TBPN · Mar 28, 2026
Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section | Diet TBPN
“Pharmaceutical company using AI agents to shorten clinical trials”
TBPN · Mar 19, 2026
FULL INTERVIEW: Mark Cuban on Robots, AI, Self-Driving, and Advice to Students
“Mentioned alongside Eli Lilly for smart direct-to-patient GLP-1 strategies”
NPR News Now · Mar 5, 2026
NPR News: 03-05-2026 5PM EST
“GLP-1 drug Ozempic discussed in study showing reduced addiction risk in diabetes patients”
Danny Jones Podcast · Feb 27, 2026
#374 - Ex-Pharma Insider Exposes the $368 Billion Health Insurance Scam | Brigham Buhler
“GLP-1 manufacturer sued compounding pharmacies; lobbies FDA against peptide accessibility”
Marketplace All-in-One · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Danish pharmaceutical company cutting Ozempic and Wegovy prices by up to 50% amid FDA regulatory pressure on compounders”
Marketplace Morning Report · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Danish pharma company cutting Ozempic and Wegovy prices by up to 50% after Trump administration pricing deals; stock down 40%”
CNBC's "Fast Money" · Feb 24, 2026
Growing AI Warnings… And Opportunities in Private Credit & Real Estate 2/24/26
“Cutting Ozempic and Wegovia prices by 50% starting next year; stock down 3% on announcement”
NPR News Now · Feb 24, 2026
NPR News: 02-24-2026 6PM EST
“Announced price cuts for Ozempic and Wegovy starting 2027, reducing list prices to $675/month following disappointing trial results”
Morning Wire · Feb 24, 2026
Evening Wire: Cartel Pressure Continues & Mamdani’s Shovel Struggles | 2.24.26
“Announced plans to cut GLP-1 drug prices by up to 50% starting 2027 amid market competition”
Motley Fool Money · Feb 24, 2026
Party Like it’s 2027
“Pharmaceutical company in litigation with Hims & Hers over GLP-1 drug distribution and marketing”
Morning Brew Daily · Feb 24, 2026
Fictional Story Tanks Stock Market & The iPod Making a Comeback?
“Danish pharma company making Ozempic; stock plunged 14% after experimental obesity drug failed to match Eli Lilly's results in trials”
CNBC's "Fast Money" · Feb 23, 2026
Tariffs, Banks & Private Credit Jitters… And Crypto Below $65K 2/23/26
“Weight loss drug competitor down 16% on disappointing Cagrasema trial results, trading at five-year lows with zero value assigned to core business”
Dr. Bob Martin Show · Feb 23, 2026
Recharge Your Body Battery: Small Choices, Big Shifts in Everyday Health
“Mentioned as competitor in trillion-dollar weight loss drug market alongside Pfizer, Viking Therapeutics, and others”
Morning Brew Daily · Feb 20, 2026
Tariffs Ineffective Against US Trade Deficit? & Family Feud Over Reese’s Recipe
“Danish pharmaceutical company; U.S. imports of Wegovy contributed to unchanged trade deficit despite tariffs”
My First Million · Feb 16, 2026
Asking Scott Galloway 10 Questions We’re Not Allowed To Ask (unfiltered)
“GLP-1 drug manufacturer; Galloway proposed government RFP for billion doses to distribute free to rural households”
Today, Explained · Feb 13, 2026
Skinny and sad on GLP-1s
“Manufacturer of brand-name GLP-1 drugs (Ozempic, Wegovy); took legal action against telehealth companies offering compounded versions”
CNBC's "Fast Money" · Feb 6, 2026
Mini Correction or Fundamental Rethinking?… And Bitcoin Bounces Back After Plunge 2/6/26
“GLP-1 manufacturer with less than 20% patent cliff exposure; stock up after FDA action against compounded competitors.”
TBPN · Feb 6, 2026
Chip Bottleneck vs. Energy Bottleneck, Amazon’s $200B Capex, Big Tech Earnings | Doug O'Laughlin, Max Levchin, TJ Parker, Arsalan Tavakoli
“Launched Wegovy pill and criticized Hims for illegal drug compounding”
Prof G Markets · Feb 5, 2026
Google Doubles Down on Spending as AI Fear Returns
“GLP-1 competitor facing market share erosion (30-40% of injectable market); oral therapy at $150/month vs prior $300-500; stock down 18% post-earnings”
Mad Money w/ Jim Cramer · Feb 5, 2026
Mad Money w/ Jim Cramer 2/4/26
“GLP-1 market leader with Ozempic/Wegovy facing pricing pressure; CEO discussed pill launch advantages and high-dose semaglutide strategy”